Open Access
Subscription Access
Open Access
Subscription Access
Anti-Arthritic and Anti-Inflammatory Effect of Cetylmyristeolate against Freund's Adjuvant Induced Arthritis Model
Subscribe/Renew Journal
To evaluate the effect of Cetylmyristeolate (CMO) in Freund's complete adjuvant induced arthritis in rats. The experimental study was evaluated on male and female Wister rats weighing (150-200gms). 0.5ml of Freund's complete adjuvant (FCA) in the left tibiotarsal joint (IA) was injected to induce arthritis, CMO-500mg;1g and CMO100mg+MSM200mg + glucosamine 500mg/day for 21 days were given. Paw edema by plesthysmometer and arthritic index were studied, the results showed marked reduction of arthritic and inflammatory effect by CMO500mg/day and 1gm/day as well as the combination of 100mg/day + glucosamine 500mg and MSM 200mg/day. Percentage inhibition of paw volume edema was statistically significant and reductions in the arthritic index scores were comparable with reference standard drug dexamethasone. From the results of this study, it was concluded that CMO as well as the combinations produced a statistically significant effect in reducing carrageenan induced arthritis in rats.
Keywords
Cetyl Myristoleate (CMO), Glucosamine Sulphate, Methyl Sulfonyl Methane (MSM), Dexamethasone, Arthritis.
Subscription
Login to verify subscription
User
Font Size
Information
- Sorensen LB, Blair JM. Rheumatologic diseases. In: Cassel CK, Cohen HJ, Larson EB, Meier DE, Resnick NM, Rubenstein LZ, Sorensen LB, editors. Geriatric medicine, New York: Springer-Verlag, 1997. p. 449.
- American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, Guidelines for the management of rheumatoid arthritis Arthr Rheum 1996;36:713 ± 722.
- Task Force on Taxonomy. Classification of chronic pain. In: H. Mersky, and N. Bogduk (Eds.), Descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed., Seattle, WA: IASP Press, 1994
- Newman SP, Revenson TA. Coping with rheumatoid arthritis. Baill. Clin. Rheum. 1993;7:259 ± 280.
- Turesson C and Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scandinavian Journal of Rheumatology 2004; 33: 65–72.
- Bansback NJ, Young A, Brennan A and Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. The Journal of Rheumatology 2006; 33: 8.
- Vogal, HG and Vogal, WH. Drug Discovery and Evaluation, Springer - Verlag berlin Heidelberg New York, 1997, P390.
- Pepys, MB., Hirschfied, GM. (2003). "C-reactive protein: a critical Update". J. Clin. Invest. 11(12):1805-12.
- Harris ED. The rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996;23(suppl 44):2–4.
- CPCSEA Guideline for laboratory animal, facility, committee for the purpose of control and supervision of experiments on animals 2004, Chennai.
- Deal CL Moskwitz RW : Nutraceuticals as Therapeutic Agents in Osteoarthritis. The role of Glucosamine, Chonroitin Sulfate and collagen Hylysate Rheum Dis Clin North Am 1999; 25 : 379–395
- Weyland CM. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 2000; 39 (Suppl.1); 3-8.
- Williams Ro. Rodent models of arthiritis : Prelevance for human disease. Clin Exp immunol 1998; 114 : 330-2.
- Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenin paw edema–possible mechanisms to increase vascular permeability inhibitory protein level which is regulated by glucocortcodis and superoxide radical. Agents action 1984: 14:123-37.
- Jasmin G (1967) Experimental arthritis in rats. A comprehensive review with specific reference to mycoplasma in: Rohstein J (ed) Rheumatology Vol.1, Karger, Basel, PP 107 -131.
Abstract Views: 328
PDF Views: 2